HRP20211107T1 - Mimetici obrambenih proteina domaćina, namijenjeni profilaksi i/ili liječenju upalnih bolesti gastrointestinalnog sustava - Google Patents
Mimetici obrambenih proteina domaćina, namijenjeni profilaksi i/ili liječenju upalnih bolesti gastrointestinalnog sustava Download PDFInfo
- Publication number
- HRP20211107T1 HRP20211107T1 HRP20211107TT HRP20211107T HRP20211107T1 HR P20211107 T1 HRP20211107 T1 HR P20211107T1 HR P20211107T T HRP20211107T T HR P20211107TT HR P20211107 T HRP20211107 T HR P20211107T HR P20211107 T1 HRP20211107 T1 HR P20211107T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- inflammatory diseases
- disease
- pmx
- prophylaxis
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims 3
- 238000011282 treatment Methods 0.000 title claims 3
- 238000011321 prophylaxis Methods 0.000 title claims 2
- 230000007123 defense Effects 0.000 title 1
- 210000001035 gastrointestinal tract Anatomy 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 4
- PWFIFNGOPQUNIT-ITMZJIMRSA-N Delparantag Chemical compound C1=C(C(N)=O)C(OC)=CC=C1NC(=O)[C@H](CCCCN)NC(=O)C1=CC(NC(=O)[C@H](CCCCN)NC(=O)C=2C(=CC=C(NC(=O)[C@H](CCCCN)NC(=O)C=3C(=CC=C(NC(=O)[C@@H](N)CCCCN)C=3)OC)C=2)OC)=CC=C1OC PWFIFNGOPQUNIT-ITMZJIMRSA-N 0.000 claims 3
- QTHBCQCKYVOFDR-PIJQHSLXSA-N 4-n,6-n-bis[3-[5-(diaminomethylideneamino)pentanoylamino]-2-[(3r)-pyrrolidin-3-yl]oxy-5-(trifluoromethyl)phenyl]pyrimidine-4,6-dicarboxamide;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.O([C@H]1CNCC1)C=1C(NC(=O)CCCCNC(=N)N)=CC(C(F)(F)F)=CC=1NC(=O)C(N=CN=1)=CC=1C(=O)NC1=CC(C(F)(F)F)=CC(NC(=O)CCCCNC(N)=N)=C1O[C@@H]1CCNC1 QTHBCQCKYVOFDR-PIJQHSLXSA-N 0.000 claims 2
- 206010056979 Colitis microscopic Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- QPDYBCZNGUJZDK-DNQXCXABSA-N brilacidin Chemical compound O([C@H]1CNCC1)C=1C(NC(=O)CCCCNC(=N)N)=CC(C(F)(F)F)=CC=1NC(=O)C(N=CN=1)=CC=1C(=O)NC1=CC(C(F)(F)F)=CC(NC(=O)CCCCNC(N)=N)=C1O[C@@H]1CCNC1 QPDYBCZNGUJZDK-DNQXCXABSA-N 0.000 claims 2
- 229950010313 brilacidin Drugs 0.000 claims 2
- 208000008609 collagenous colitis Diseases 0.000 claims 2
- 210000005095 gastrointestinal system Anatomy 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000004341 lymphocytic colitis Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229950000132 delparantag Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (4)
1. Farmaceutski pripravak namijenjen upotrebi u liječenju upalnih bolesti gastrointestinalnog sustava, koje se bira između upalne bolesti crijeva, ulceroznog kolitisa, kolagenoznog kolitisa, limfocitnog kolitisa, Crohnove bolesti, te sindroma iritabilnih crijeva, naznačen time što navedeni pripravci sadrže terapijski djelotvornu količinu spoja kojeg se bira između PMX-30063 (brilacidina) i PMX-60056 (delparantaga) i njihovih farmaceutski prihvatljivih soli, kao i farmaceutski prihvatljivi nosač.
2. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se navedeni spoj primijenjuje zajedno s antibiotikom.
3. Spoj kojeg se bira između PMX-30063 (brilacidina) i PMX-60056 (delparantaga) i njihovih farmaceutski prihvatljivih soli, ili farmaceutski pripravci koji sadrže iste, naznačeni time što su namijenjen upotrebi u profilaksi i/ili liječenju upalnih bolesti gastrointestinalnog sustava kod pacijenta, gdje se navedenu bolest bira između upalne bolesti crijeva, ulceroznog kolitisa, kolagenoznog kolitisa, limfocitnog kolitisa, Crohnove bolesti, te sindroma iritabilnih crijeva.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je namijenjen upotrebi u kombinaciji s antibiotikom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118950P | 2015-02-20 | 2015-02-20 | |
| EP16752799.3A EP3258927B8 (en) | 2015-02-20 | 2016-02-09 | Host defense protein (hdp) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract |
| PCT/US2016/017061 WO2016133733A1 (en) | 2015-02-20 | 2016-02-09 | Host defense protein (hdp) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211107T1 true HRP20211107T1 (hr) | 2021-10-15 |
Family
ID=56689106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211107TT HRP20211107T1 (hr) | 2015-02-20 | 2021-07-12 | Mimetici obrambenih proteina domaćina, namijenjeni profilaksi i/ili liječenju upalnih bolesti gastrointestinalnog sustava |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20160243117A1 (hr) |
| EP (1) | EP3258927B8 (hr) |
| JP (1) | JP6047203B2 (hr) |
| CN (1) | CN107613967A (hr) |
| AU (1) | AU2016220373B2 (hr) |
| DK (1) | DK3258927T3 (hr) |
| ES (1) | ES2881429T3 (hr) |
| HR (1) | HRP20211107T1 (hr) |
| HU (1) | HUE055090T2 (hr) |
| LT (1) | LT3258927T (hr) |
| PL (1) | PL3258927T3 (hr) |
| PT (1) | PT3258927T (hr) |
| RS (1) | RS62249B1 (hr) |
| SI (1) | SI3258927T1 (hr) |
| WO (1) | WO2016133733A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| WO2012158672A2 (en) * | 2011-05-16 | 2012-11-22 | Polymedix, Inc. | Compounds for use in treatment of mucositis |
| PE20181295A1 (es) | 2015-09-01 | 2018-08-07 | First Wave Bio Inc | Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala |
| JP2022516662A (ja) * | 2019-01-08 | 2022-03-01 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| WO2021248008A1 (en) | 2020-06-05 | 2021-12-09 | Innovation Pharmaceuticals Inc. | Arylamide compounds for treatment and prevention of viral infections |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629317B2 (en) * | 2001-03-29 | 2009-12-08 | The University Of Chicago | Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors |
| JP5209302B2 (ja) * | 2004-06-15 | 2013-06-12 | ポリメディックス、インク． | ポリカチオン化合物とその使用 |
| US8017576B2 (en) * | 2005-05-10 | 2011-09-13 | The University Of Chicago | Methods and compositions to treat mucositis |
| US8202835B2 (en) * | 2005-06-17 | 2012-06-19 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
| US20090092574A1 (en) * | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| TWI478915B (zh) * | 2008-10-27 | 2015-04-01 | Cellceutix Corp | 宿主防禦之合成模擬物及其用途 |
| WO2012158672A2 (en) * | 2011-05-16 | 2012-11-22 | Polymedix, Inc. | Compounds for use in treatment of mucositis |
-
2015
- 2015-06-12 JP JP2015119056A patent/JP6047203B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-09 PT PT167527993T patent/PT3258927T/pt unknown
- 2016-02-09 RS RS20210876A patent/RS62249B1/sr unknown
- 2016-02-09 EP EP16752799.3A patent/EP3258927B8/en active Active
- 2016-02-09 AU AU2016220373A patent/AU2016220373B2/en not_active Ceased
- 2016-02-09 CN CN201680024015.9A patent/CN107613967A/zh active Pending
- 2016-02-09 SI SI201631265T patent/SI3258927T1/sl unknown
- 2016-02-09 HU HUE16752799A patent/HUE055090T2/hu unknown
- 2016-02-09 WO PCT/US2016/017061 patent/WO2016133733A1/en active Application Filing
- 2016-02-09 ES ES16752799T patent/ES2881429T3/es active Active
- 2016-02-09 DK DK16752799.3T patent/DK3258927T3/da active
- 2016-02-09 PL PL16752799T patent/PL3258927T3/pl unknown
- 2016-02-09 LT LTEPPCT/US2016/017061T patent/LT3258927T/lt unknown
- 2016-02-12 US US15/042,923 patent/US20160243117A1/en not_active Abandoned
-
2020
- 2020-08-12 US US16/991,812 patent/US11666571B2/en active Active
-
2021
- 2021-07-12 HR HRP20211107TT patent/HRP20211107T1/hr unknown
-
2023
- 2023-05-08 US US18/313,991 patent/US20230310435A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3258927B1 (en) | 2021-06-09 |
| EP3258927A1 (en) | 2017-12-27 |
| ES2881429T3 (es) | 2021-11-29 |
| CN107613967A (zh) | 2018-01-19 |
| US20230310435A1 (en) | 2023-10-05 |
| US20200368232A1 (en) | 2020-11-26 |
| JP6047203B2 (ja) | 2016-12-21 |
| RS62249B1 (sr) | 2021-09-30 |
| WO2016133733A1 (en) | 2016-08-25 |
| US20160243117A1 (en) | 2016-08-25 |
| DK3258927T3 (da) | 2021-07-19 |
| HUE055090T2 (hu) | 2021-10-28 |
| AU2016220373B2 (en) | 2020-10-22 |
| EP3258927A4 (en) | 2018-11-21 |
| SI3258927T1 (sl) | 2022-03-31 |
| AU2016220373A1 (en) | 2017-10-12 |
| PT3258927T (pt) | 2021-07-22 |
| US11666571B2 (en) | 2023-06-06 |
| LT3258927T (lt) | 2021-09-27 |
| PL3258927T3 (pl) | 2021-11-08 |
| EP3258927B8 (en) | 2021-09-15 |
| JP2016153386A (ja) | 2016-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211107T1 (hr) | Mimetici obrambenih proteina domaćina, namijenjeni profilaksi i/ili liječenju upalnih bolesti gastrointestinalnog sustava | |
| JP2015078220A5 (hr) | ||
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| HRP20201812T1 (hr) | Modulatori proteina jezgre hepatitisa b | |
| EA201891489A1 (ru) | Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант | |
| WO2015181356A8 (en) | Vaccine composition against streptococcus suis infection | |
| HRP20221294T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| EA201490610A1 (ru) | Соединения и способы усиления врожденных иммунных ответов | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2016027901A5 (hr) | ||
| JP2015537009A5 (hr) | ||
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| RU2015139758A (ru) | Хиназолины в качестве ингибиторов киназы | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| WO2016020880A3 (en) | Angiopoietin-like 4 antibodies and methods of use | |
| WO2016020882A3 (en) | Angiopoetin-like 4 (angptl4) antibodies and methods of use | |
| WO2015160907A3 (en) | Potent and selective inhibitors of hepatitis c virus | |
| EA201890412A1 (ru) | АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| HRP20191434T1 (hr) | Liječenje eritromelalgije | |
| MA42611A (fr) | Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines | |
| EA201792314A1 (ru) | Фармацевтическая комбинация эверолимуса и дактолисиба | |
| JP2017517561A5 (hr) | ||
| MD4763B1 (ro) | Compoziţie farmaceutică |